scholarly journals Endocrine-Resistant Breast Cancer: Mechanisms and Treatment

Breast Care ◽  
2020 ◽  
Vol 15 (4) ◽  
pp. 347-354
Author(s):  
Andreas D. Hartkopf ◽  
Eva-Maria Grischke ◽  
Sara Y. Brucker
Keyword(s):  
Breast Cancer ◽  
Molecular Mechanisms ◽  
Acquired Resistance ◽  
Endocrine Resistance ◽  
Optimal Combination ◽  
Endocrine Treatment ◽  
Esr1 Gene ◽  
Pi3k Inhibition ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Background: Endocrine treatment is one of the most effective therapies for estrogen receptor-positive breast cancer. However, most tumors will develop resistance to endocrine therapy as the cancer progresses. This review focuses on the mechanisms and markers of endocrine-resistant breast cancer. In addition, current and future strategies to overcome endocrine resistance are discussed. Summary: Several molecular mechanisms of endocrine resistance have been identified, including alterations in the ESR1 gene or in the PIK3CA/mTOR pathway. Meanwhile, CDK4/6, mTOR, and PI3K inhibition have shown to improve the efficacy of endocrine treatment and new promising approaches are being developed. Key Message: Overcoming primary or acquired resistance to endocrine treatment remains a major challenge. Since the molecular mechanisms of endocrine resistance are manifold, optimal combination and sequencing strategies will have to be developed in the future.

scholarly journals Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Esmael Besufikad Belachew ◽  
Dareskedar Tsehay Sewasew
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Therapy ◽  
Molecular Mechanisms ◽  
De Novo ◽  
Endocrine Resistance ◽  
Therapeutic Modality ◽  
Breast Cancers ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive breast cancer. The main strategy for the treatment of estrogen receptor-positive breast cancers is blocking the estrogen action on estrogen receptors by endocrine therapy but this can be restricted via endocrine resistance. Endocrine resistance occurs due to both de novo and acquired resistance. This review focuses on the mechanisms of the ligand-dependent and ligand-independent pathways and other coregulators, which are responsible for endocrine resistance. It concludes that combinatorial drugs that target different signaling pathways and coregulatory proteins together with endocrine therapy could be a novel therapeutic modality to stop endocrine resistance.

scholarly journals Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

2018 ◽  
Vol 24 (10) ◽  
pp. 2452-2463 ◽  
Author(s):  
Luke Piggott ◽  
Andreia Silva ◽  
Timothy Robinson ◽  
Angelica Santiago-Gómez ◽  
Bruno M. Simões ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acquired Resistance ◽  
Endocrine Treatment ◽  
Er Positive ◽  
Positive Breast Cancer

Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

2020 ◽  
Author(s):  
Bo Liu ◽  
Dara S. Ross ◽  
Alison M. Schram ◽  
Pedram Razavi ◽  
Stephen M. Lagana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Resistance ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Detection of spliceomic signatures for predicting endocrine resistance in estrogen receptor-positive breast cancer

The Breast ◽  
2017 ◽  
Vol 32 ◽  
pp. S40-S41
Author(s):  
H.-B. Lee ◽  
M. Kim ◽  
Y.-J. Kang ◽  
E.-S. Lee ◽  
J. Rhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Endocrine Resistance ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document